Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact

Isin IT0003828271
Ticker REC.MI
Aware Investor Index (AII) 0.0470
Recommendation SELL
P/E 77.77
ROE 13.87 %
Capitalization 10,199,164,760 $
Dividend Yield 1.31 %
P/S 8.96
AII Position 559
P/E Position 701
ROE Position 281
Capitalization Position 495
Dividend Yield Position 462
Sales 1,047,676,000 €
10-Year Average Earnings 120,708,500 €
Shares Outstanding 205,270,094
Equity 869,992,000 €
Dividend per Share 0.6 €
Industry Pharmaceutical
Country Italy
RECORDATI Investor Relations Web Site http://www.recordati.it/it/investors/


2015 12 1,047,676,000.00 €
2014 12 987,356,000.00 €
2013 12 941,630,000.00 €


2015 12 198,803,000.00 €
2014 12 161,193,000.00 €
2013 12 133,693,000.00 €
2012 12 118,500,000.00 €
2011 12 116,400,000.00 €
2010 12 108,600,000.00 €
2009 12 110,600,000.00 €
2008 12 100,400,000.00 €
2007 12 84,865,000.00 €
2006 12 74,031,000.00 €


2015 12 869,992,000.00 €
2014 12 787,422,000.00 €
2013 12 701,820,000.00 €
2012 12 661,397,000.00 €

Shares Outstanding:

2015 12 205,270,094
2014 12 204,417,486
2013 12 202,615,046
2012 12 200,619,366


Bloomberg News for RECORDATI:

Dec 18, 2017
Brokers Launch Funds to Prove Their Worth as MiFID Threat Looms
strategy the research firm sells to clients.“If we didn’t have this, I’d be panicking” because of MiFID, said McCreery, founder of the London-based provider of quant-based fundamental research. “We...
Dec 15, 2017
MiFID Bond-Price Rules a Gift for Traders as Just 1% Covered
initially captured by MiFID II means the law’s goal of shedding light on the market may not be achieved anytime soon.Bloomberg QuickTake looks at how banking will change under MiFID II. (Source: Bloomberg)“ESMA’s...
Dec 18, 2017
How Systematic Internalizers Will Change Trading
Reference ShelfA QuickTake Q&A on how dark trading will still thrive under MiFID II. QuickTake explainers on dark pools and MiFID.An interview with the head of the EU’s markets regulator. ...
Dec 13, 2017
Lightspeed's Mi Expects More China FinTech IPOs
James Mi, Lightspeed China Partners managing director, discusses the trend of Chinese financial tech firms...
Dec 13, 2017
AGI's Utermann Sees No MiFID II Market Disruptions
Andreas Utermann, chief executive officer at Allianz Global Investors, discusses the market impact of MiFID II and how the new rules will change the way the firm pays for research. He speaks with Bloomberg's...
Dec 12, 2017
EU's Dombrovskis on Climate Change, MiFID II, Basel
European Commission Vice President Valdis Dombrovskis discusses steps to combating climate change, MiFID II transposition, Brexit, and Basel standards. He speaks with Bloomberg's Mark Barton from the...
Dec 12, 2017
Goldman Sachs Plans MiFID II Venue for Bonds, ETFs, Derivatives
of Europe’s MiFID II laws, one of the most wide-sweeping trading plans by a bank under the new rules.Goldman Sachs will operate a so-called systematic internalizer from Jan. 3 when MiFID kicks in...
Dec 18, 2017
IG, Plus500 Plunge as EU Watchdog Signals Derivatives Crackdown
Securities and Markets Authority, using powers set out in the overhaul of financial rules known as MiFID II, outlined late Friday how it may curb leverage, limit how much clients can lose on the contracts...
Dec 13, 2017
Full Show: Bloomberg Technology (12/13)
T-Mobile COO Mike Sievert, Juniper Networks CEO Rami Rahim and Lightspeed China Partners' James Mi. ...
Dec 18, 2017
Can Mitchonomics Fix the Broken Business of Higher Ed?
getting less state funding. Some, including the University of California at Berkeley, UCLA, Michigan, North Carolina, Texas, and Virginia, have replaced that loss with a combination of jacked-up...

Google News for RECORDATI:

MarketWatch - 21 May 2017
AstraZeneca, Recordati agree Seloken rights deal
LONDON--AstraZeneca PLC (AZN.LN) has entered into an agreement with Recordati S.p.A (REC.MI) for the commercial rights to AstraZeneca's heart-failure drug Seloken/Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe. AstraZeneca said Monday that Recordati will pay ...
The Pharma Letter - 13 Apr 2017
Recordati Rare Diseases Canada launched
Recordati Rare Diseases Canada, a company wholly-owned by the Italy-based Recordati Group (REC: MI), will be the exclusive provider of several treatments, including Carbaglu (carglumic acid), Cystadane (betaine anhydrous) and Cosmegen (dactinomycin) in Canada. "We're thrilled to be a part of ...
fabiotroglia.com (Blog) - 21 Jul 2016
Azioni Recordati, la pharma italiana che continua a brillare
Per noi non ci sono limiti per ora, abbiamo acquistato le azioni di Recordati (REC.MI) nel febbraio 2014 a 12 euro, puntavamo come target i 20 euro ma la societ non ha mai smesso di crescere e cos, tuttora, performa nel nostro portafoglio il +138%. Il nostro nuovo target price sono i 32 euro, dopo i quali ...